EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck

 EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck

EMD Serono and Pfizer to Terminate its P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck

Shots:

  • The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA SCCHN
  • The companies have accepted DMC’s recommendation to terminate the P-III JAVELIN Head and Neck 100 study as it did not meet its 1EPs i.e. improvement in PFS. A detailed analysis of the Phase III JAVELIN Head and Neck 100 study is being conducted and results will be shared with the scientific community
  • Bavencio is a PD-L1 antibody, acts by blocking the interaction of PD-L1 with PD-1 receptors. In Nov’2014, Merck KGaA and Pfizer signed an agreement to co-develop and co-commercialize Bavencio

Click here ­to­ read full press release/ article | Ref: EMD Sereno | Image: Blau Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post